Comprehensive medication guide to Yusimry including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$0 to $50 per prescription with commercial insurance and the Yusimry Solutions Copay Card; prior authorization is typically required; not on preferred tier for most major PBM formularies, which may result in higher step-therapy or non-preferred cost-sharing without a PA.
Estimated Cash Pricing
$995 per carton (2 x 40 mg autoinjectors) at list price; as low as $569.27 plus dispensing/shipping fees through Cost Plus Drugs (costplusdrugs.com) for a 4-week supply.
Medfinder Findability Score
42/100
Summarize with AI
On this page
Yusimry (adalimumab-aqvh) is an FDA-approved biosimilar to Humira (adalimumab), the world's former best-selling biologic drug. Developed by Coherus BioSciences and distributed by Meitheal Pharmaceuticals, Yusimry received FDA approval on December 17, 2021 and launched commercially in July 2023. It is the seventh adalimumab biosimilar approved in the United States.
A biosimilar is a biological medicine that is highly similar to an already-approved reference product — in this case, Humira — with no clinically meaningful differences in safety, purity, or potency. Yusimry meets all FDA-required criteria to confirm biosimilarity to Humira.
Yusimry is supplied as a 40 mg/0.8 mL subcutaneous injection, available in both a prefilled glass syringe and a prefilled autoinjector pen. The formula is citrate-free and latex-free, which may improve comfort for some patients. Importantly, Yusimry does NOT hold FDA interchangeable designation — unlike some other adalimumab biosimilars — meaning pharmacists cannot substitute it for Humira at the counter without explicit prescriber authorization.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Yusimry is a TNF-alpha inhibitor (also called a TNF blocker or anti-TNF biologic). It works by binding specifically to tumor necrosis factor-alpha (TNF-alpha) — a naturally occurring protein in the immune system — and blocking its interaction with cell surface TNF receptors. This interrupts the inflammatory cascade that drives many autoimmune diseases.
In conditions like rheumatoid arthritis, elevated TNF-alpha concentrations in synovial fluid drive joint inflammation and structural damage. In Crohn's disease and ulcerative colitis, TNF-alpha fuels gut inflammation. In plaque psoriasis, it drives overproduction of skin cells. By blocking TNF-alpha, Yusimry reduces inflammation, pain, and tissue damage across all of these conditions.
Because TNF-alpha also plays an important role in immune defense — particularly against tuberculosis and certain fungal infections — blocking it with Yusimry increases infection risk. This is why TB screening is required before starting Yusimry, and why the medication carries a black box warning for serious infections.
40 mg/0.8 mL — Prefilled autoinjector pen
Single-dose prefilled pen; citrate-free and latex-free
40 mg/0.8 mL — Prefilled glass syringe
Single-dose prefilled syringe; citrate-free and latex-free
Yusimry is not in an official FDA shortage, but it is genuinely difficult to find at most retail pharmacies. The core problem is market dynamics: the three largest pharmacy benefit managers (CVS Caremark, Express Scripts, OptumRx) have private-label arrangements with other adalimumab biosimilars, giving Yusimry only about 3% of adalimumab market share. Pharmacies stock what their biggest payer contracts demand — and those contracts rarely include Yusimry.
Yusimry's best availability channels are specialty pharmacies and Cost Plus Drugs (costplusdrugs.com), where it is offered at $569.27 plus fees — the most affordable cash price for any adalimumab biosimilar. Patients whose insurance doesn't cover Yusimry may find Cost Plus Drugs to be their most practical option.
To find which pharmacies near you have Yusimry in stock, use medfinder — enter your medication, dosage, and location, and medfinder calls pharmacies on your behalf and texts you the results.
Yusimry is not a controlled substance and has no special DEA prescribing requirements. Any licensed prescriber — physician (MD, DO), nurse practitioner (NP), or physician assistant (PA) — can legally prescribe it. However, because it treats serious autoimmune conditions requiring specialist evaluation, Yusimry is almost always prescribed by specialists, and prior authorization requires documentation from a specialist in most cases.
Rheumatologists — for RA, psoriatic arthritis, ankylosing spondylitis, JIA
Gastroenterologists — for Crohn's disease, ulcerative colitis
Dermatologists — for plaque psoriasis, hidradenitis suppurativa
Ophthalmologists — for non-infectious uveitis
Nurse Practitioners and Physician Assistants — can prescribe independently in most states; often work within specialist practices
Telehealth options are limited for initial Yusimry prescriptions since an in-person evaluation is generally needed to establish the diagnosis and complete required pre-treatment screening (TB test, HBV screening). Ongoing management of stable patients may be possible via telehealth rheumatology or gastroenterology services.
No. Yusimry (adalimumab-aqvh) is not a controlled substance and is not scheduled by the DEA. It is a biologic medication — a specialty drug — but has no abuse potential or addiction risk. Any licensed prescriber (physician, nurse practitioner, or physician assistant) can prescribe Yusimry without special DEA registration or restricted prescribing authority.
While not a controlled substance, Yusimry is a specialty medication that typically requires prior authorization from insurance and dispensing through a specialty pharmacy. It also carries an FDA black box warning for serious infections and malignancy, which are important safety considerations unrelated to controlled substance status.
Injection site reactions (redness, itching, pain, swelling) — most common, ~20% of patients
Upper respiratory infections (sinusitis, sore throat, cold symptoms)
Headache
Rash
Nausea
Serious infections including tuberculosis, bacterial sepsis, and invasive fungal infections (BLACK BOX WARNING)
Lymphoma and other malignancies, particularly in children/adolescents (BLACK BOX WARNING)
Hepatitis B reactivation
New or worsening congestive heart failure
Demyelinating disease (numbness, vision changes, weakness)
Blood dyscrasias (pancytopenia, aplastic anemia)
Lupus-like syndrome
Severe allergic/anaphylactic reactions
Know what you need? Skip the search.
Humira (adalimumab)
Original reference biologic; same mechanism and indications; significantly higher list price (~$6,922/carton vs $995 for Yusimry).
Amjevita (adalimumab-atto)
Amgen biosimilar; FDA interchangeable; preferred by OptumRx. Available in low- and high-concentration forms.
Cyltezo (adalimumab-adbm)
Boehringer Ingelheim; first interchangeable biosimilar designation; preferred by Express Scripts.
Hyrimoz (adalimumab-adaz)
Sandoz; interchangeable; CVS Caremark preferred (Cordavis private-label). High-concentration option available.
Etanercept (Enbrel)
Different TNF inhibitor (fusion protein); approved for RA, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis; weekly injection.
Upadacitinib (Rinvoq)
Oral JAK inhibitor approved for RA, PsA, AS, UC, CD, and atopic dermatitis; alternative for patients who prefer a pill over injection.
Prefer Yusimry? We can find it.
Anakinra (Kineret)
majorCombination with anakinra increases serious infection risk and neutropenia; not recommended.
Abatacept (Orencia)
majorCombination increases serious infection risk with no added benefit in RA; not recommended.
Live vaccines (MMR, varicella, yellow fever, nasal flu)
majorLive vaccines must not be administered during Yusimry therapy due to immunosuppression risk.
Other TNF blockers
majorConcurrent use of two TNF inhibitors increases infection risk with no clinical benefit; avoid.
Rituximab
moderateHigher rate of serious infections seen when TNF blocker follows rituximab therapy; monitor closely.
Warfarin
moderateYusimry may affect CYP450 enzyme activity; monitor INR when starting or stopping Yusimry.
Cyclosporine
moderateCYP450 interaction; monitor cyclosporine blood levels when starting or stopping Yusimry.
Azathioprine / 6-mercaptopurine
moderateCombination associated with hepatosplenic T-cell lymphoma in young males with IBD; use with caution.
Methotrexate
minorFrequently combined with Yusimry in RA; may enhance efficacy and reduce immunogenicity. Generally well tolerated.
Yusimry (adalimumab-aqvh) is a clinically proven biosimilar offering significant cost savings compared to Humira. At $995 per carton list price — and as low as $569.27 through Cost Plus Drugs — it is the most affordable adalimumab option by list price. For commercially insured patients, the Yusimry Solutions Copay Card can reduce costs to as little as $0 per prescription.
The main challenge with Yusimry is not efficacy or safety — it is market access. Without a private-label deal with the major PBMs, Yusimry has limited retail pharmacy shelf space and may face formulary barriers at many insurance plans. Patients who are prescribed Yusimry often need help finding it.
If you're struggling to fill your Yusimry prescription, medfinder can help. Enter your medication, dosage, and location — medfinder calls pharmacies near you to find which ones have Yusimry in stock and can fill your prescription, then texts you the results.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini